• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

慢性腰痛中美沙酮颊膜和透皮贴剂的经济负担和用药趋势。

Economic burden and dosing trends of buprenorphine buccal film and transdermal patch in chronic low back pain.

机构信息

Health Economics & Outcomes Research Department, ZRx Outcomes Research Inc., Mississauga, ON L5A 2X7, Canada.

出版信息

Pain Manag. 2024;14(4):195-207. doi: 10.1080/17581869.2024.2348989. Epub 2024 May 31.

DOI:10.1080/17581869.2024.2348989
PMID:38939964
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11229441/
Abstract

Exploring prescribing trends and economic burden of chronic low back pain (cLBP) patients prescribed buprenorphine buccal film (Belbuca®) or transdermal patches. In the MarketScan® commercial insurance claims (employees and their spouses/dependents, 2018-2021), the first film or patch prescription date was an index event. The observation covered 6-month pre-index and 12-month post-index periods. Patients were propensity-score matched (708 per cohort). Buprenorphine initiation had stable cost trends in buccal film and increasing trends in transdermal patch cohort. Between-cohort comparisons of healthcare expenditures, cost trends and resource utilization showed significant differences, mostly in favor of buccal film. Buccal film also had higher daily doses and wider dosing range. Buprenorphine film is more cost-effective cLBP treatment with more flexible dosing.

摘要

探索处方趋势和接受丁丙诺啡颊膜（Belbuca®）或透皮贴剂治疗的慢性下背痛（cLBP）患者的经济负担。在 MarketScan®商业保险索赔（员工及其配偶/受抚养人，2018-2021 年）中，第一次使用颊膜或贴剂的处方日期为索引事件。观察期包括 6 个月的索引前和 12 个月的索引后。采用倾向评分匹配（每个队列 708 人）。丁丙诺啡的起始使用在颊膜中有稳定的成本趋势，而在透皮贴剂队列中则呈上升趋势。两组间的医疗支出、成本趋势和资源利用比较显示出显著差异，主要有利于颊膜。颊膜的日剂量更高，剂量范围更广。丁丙诺啡膜是更具成本效益的 cLBP 治疗方法，具有更灵活的给药方式。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d9/11229441/ab6f4bb1c1b7/IPMT_A_2348989_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d9/11229441/89a77e5c6377/IPMT_A_2348989_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d9/11229441/25252057ce05/IPMT_A_2348989_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d9/11229441/ab6f4bb1c1b7/IPMT_A_2348989_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d9/11229441/89a77e5c6377/IPMT_A_2348989_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d9/11229441/25252057ce05/IPMT_A_2348989_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8d9/11229441/ab6f4bb1c1b7/IPMT_A_2348989_F0003_C.jpg

相似文献

1
Economic burden and dosing trends of buprenorphine buccal film and transdermal patch in chronic low back pain.慢性腰痛中美沙酮颊膜和透皮贴剂的经济负担和用药趋势。
Pain Manag. 2024;14(4):195-207. doi: 10.1080/17581869.2024.2348989. Epub 2024 May 31.
2
Treatment characteristics of chronic low back pain patients treated with buprenorphine buccal film or transdermal patch.接受丁丙诺啡口腔膜片或透皮贴剂治疗的慢性腰痛患者的治疗特征。
Pain Manag. 2024 Jan;14(1):35-48. doi: 10.2217/pmt-2023-0124. Epub 2024 Jan 18.
3
Serious treatment-emergent adverse events in chronic low back pain patients treated with buprenorphine or oral opioids: a retrospective commercial claims analysis.在接受丁丙诺啡或口服阿片类药物治疗的慢性腰痛患者中严重的治疗中出现的不良事件：一项回顾性商业索赔分析。
J Comp Eff Res. 2024 Aug;13(8):e230183. doi: 10.57264/cer-2023-0183. Epub 2024 Jul 16.
4
US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system.美国使用丁丙诺啡透皮贴剂系统进行新治疗的从业者处方习惯及患者特征。
Curr Med Res Opin. 2014 Aug;30(8):1579-87. doi: 10.1185/03007995.2014.901941. Epub 2014 Apr 4.
5
Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain.口腔含服丁丙诺啡对中度至重度慢性下腰痛的阿片类药物初治患者的疗效和耐受性
Postgrad Med. 2016 Jan;128(1):1-11. doi: 10.1080/00325481.2016.1128307. Epub 2015 Dec 22.
6
Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights.使用相互竞争的EQ-5D权重评估丁丙诺啡治疗慢性疼痛的成本效益。
Scand J Pain. 2015 Jan 1;6(1):24-30. doi: 10.1016/j.sjpain.2014.07.002.
7
Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain.与安慰剂相比，丁丙诺啡透皮贴剂可减少慢性下腰痛对功能的干扰。
Postgrad Med. 2015 Jan;127(1):38-45. doi: 10.1080/00325481.2014.992715. Epub 2014 Dec 15.
8
Buprenorphine buccal film for chronic pain management.丁丙诺啡颊膜用于慢性疼痛管理。
Pain Manag. 2020 Jul;10(4):213-223. doi: 10.2217/pmt-2020-0013. Epub 2020 May 12.
9
Buprenorphine transdermal system utilization.丁丙诺啡透皮贴剂的使用情况。
Postgrad Med. 2017 Jan;129(1):81-86. doi: 10.1080/00325481.2017.1267537. Epub 2016 Dec 15.
10
Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain.丁丙诺啡透皮贴剂治疗慢性腰痛伴阿片类药物使用史患者的疗效和生活质量。
Expert Opin Pharmacother. 2013 Feb;14(3):269-77. doi: 10.1517/14656566.2013.767331.

本文引用的文献

1
Treatment characteristics of chronic low back pain patients treated with buprenorphine buccal film or transdermal patch.接受丁丙诺啡口腔膜片或透皮贴剂治疗的慢性腰痛患者的治疗特征。
Pain Manag. 2024 Jan;14(1):35-48. doi: 10.2217/pmt-2023-0124. Epub 2024 Jan 18.
2
Analgesic Effect of Buprenorphine for Chronic Noncancer Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials.布比卡因用于慢性非癌性疼痛的镇痛效果：随机对照试验的系统评价和荟萃分析。
Anesth Analg. 2023 Jul 1;137(1):59-71. doi: 10.1213/ANE.0000000000006467. Epub 2023 Jun 16.
3
Global, regional and national burden of low back pain 1990-2019: A systematic analysis of the Global Burden of Disease study 2019.
1990 - 2019年全球、区域和国家腰痛负担：全球疾病负担研究2019的系统分析
J Orthop Translat. 2021 Sep 10;32:49-58. doi: 10.1016/j.jot.2021.07.005. eCollection 2022 Jan.
4
Benefit-Risk Analysis of Buprenorphine for Pain Management.丁丙诺啡用于疼痛管理的获益-风险分析。
J Pain Res. 2021 May 24;14:1359-1369. doi: 10.2147/JPR.S305146. eCollection 2021.
5
Risk Factors Associated With Transition From Acute to Chronic Low Back Pain in US Patients Seeking Primary Care.与美国寻求初级保健的患者从急性腰痛向慢性腰痛转变相关的风险因素。
JAMA Netw Open. 2021 Feb 1;4(2):e2037371. doi: 10.1001/jamanetworkopen.2020.37371.
6
Health Care Resource Utilization and Management of Chronic, Refractory Low Back Pain in the United States.美国慢性难治性腰痛的医疗资源利用与管理。
Spine (Phila Pa 1976). 2020 Oct 15;45(20):E1333-E1341. doi: 10.1097/BRS.0000000000003572.
7
Buprenorphine buccal film for chronic pain management.丁丙诺啡颊膜用于慢性疼痛管理。
Pain Manag. 2020 Jul;10(4):213-223. doi: 10.2217/pmt-2020-0013. Epub 2020 May 12.
8
Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain.新型阿片类药物丁丙诺啡治疗慢性疼痛的安全性与有效性
J Pain Res. 2019 Dec 13;12:3299-3317. doi: 10.2147/JPR.S231948. eCollection 2019.
9
A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain.丁丙诺啡的叙述性药理学综述：一种用于治疗慢性疼痛的独特阿片类药物。
Pain Ther. 2020 Jun;9(1):41-54. doi: 10.1007/s40122-019-00143-6. Epub 2020 Jan 28.
10
Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion.理解丁丙诺啡在慢性疼痛中的应用：专家意见。
Pain Med. 2020 Apr 1;21(4):714-723. doi: 10.1093/pm/pnz356.